Highlights SCYNEXIS, Inc.

Equities

SCYX

US8112922005

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-30 pm EDT			5-day change	1st Jan Change
1.69 ^USD	-7.14%		+9.03%	-24.22%

Apr. 09	SCYNEXIS, Inc. to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases	CI
Mar. 28	SCYNEXIS, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

SCYNEXIS, Inc. to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases	Apr. 09	CI
SCYNEXIS, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
SCYNEXIS, Inc. Presents Preclinical Data on Second Generation Fungerp SCY-247 Against Mucormycosis At the 11Th Advances Against Aspergillosis and Mucormycosis Conference	Jan. 29	CI
SCYNEXIS Amends License Agreement With GlaxoSmithKline Intellectual Property; Shares Drop Premarket	Jan. 03	MT
Earnings Flash (SCYX) SCYNEXIS Reports Q3 Revenue $1.8M	Nov. 13	MT
SCYNEXIS, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
SCYNEXIS, Inc. Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology	23-10-24	CI
SCYNEXIS, Inc. Issues A Voluntary Nationwide Recall of BREXAFEMME® (Ibrexafungerp Tablets) Due to Potential for Cross Contamination with A Non-Antibacterial ß-Lactam Drug Substance	23-09-27	CI
Earnings Flash (SCYX) SCYNEXIS Posts Q2 Revenue $131.5M	23-08-14	MT
SCYNEXIS, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
SCYNEXIS, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
SCYNEXIS : 10-K Filing	23-03-31	PU
SCYNEXIS INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	23-03-31	AQ
Earnings Flash (SCYX) SCYNEXIS Posts Q4 Revenue $1.4M	23-03-31	MT
SCYNEXIS, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
GSK sees $500 million peak sales for yeast infection pill licensed from Scynexis	23-03-30	RE
GSK plc and SCYNEXIS, Inc. Announce an Exclusive Agreement to Commercialise Brexafemme (Ibrexafungerp Tablets)	23-03-30	CI
GSK, Scynexis Sign License Deal for Fungal Infection Treatment	23-03-30	MT
GSK Secures Rights to Commercialize Brexafemme Under Exclusive Deal with Scynexis	23-03-30	MT
SCYNEXIS, Inc. Enters into License Agreement with Glaxosmithkline Intellectual Property (No. 3) Limited	23-03-30	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights SCYNEXIS, Inc.

Equities

SCYX

US8112922005

Highlights

Filters